Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
SAN DIEGO, May 03, 2018 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, May 10, 2018 at 5:00 p.m. ET to report its first quarter 2018 financial results and provide a corporate update.
In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 5592629. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Fate Therapeutics is headquartered in San Diego, CA.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]
